Trial intelligence / Profile preview

Erlotinib and Bevacizumab in Advanced Ovarian Cancer

NCT00130520Phase 2Completed

Sponsor
University of Arizona
Start
Jun 2005
Primary completion
Jan 2010
Modality
Small Molecules, Monoclonal Antibodies
Countries
1
01

Overview

A Phase 2 trial of erlotinib, bevacizumab in ovarian cancer, primary peritoneal carcinoma (PPC), sponsored by University of Arizona. Started Jun 2005; status: completed.

02

Drugs

erlotinibbevacizumab
03

Conditions

ovarian cancerprimary peritoneal carcinoma (PPC)

Beyond the preview

Go deeper on NCT00130520.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00130520.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call